receptor-tyrosine kinase inhibitor - Globe Thesis

Keyword [receptor-tyrosine kinase inhibitor] Result: 21 - 40 \| Page: 2 of 5
21.	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor As Maintenance Therapy For Advanced Non-Small-Cell Lung Cancer: A Meta-analysis Of Randomized Controlled Trials
22.	The Effect And Mechanism Of Sunitinib On Proliferation And Apoptosis In HaCat Cells Induced By EGF
23.	Comparison Of The Efficacy Of TKI In Patients Diagnosed With Advanced Lung Adenocarcinoma, Harboring Different EGFR, KRAS Mutation Status
24.	Individualized Therapy Of Advanced Non-small Cell Lung Cancer With Acquired Resistance To Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
25.	Caveolin-1 Decreases The Sensibility To TKIs In Non-small Cell Lung Cancer Harboring EGFR Mutations
26.	Clinical Observation Of Targeted Drugs As A Therapy On Advanced Non-small Cell Lung Cancer
27.	Erlotinib Enhanced The CIK Cell-mediated Lysis To Lung Adenocarcinoma HCC827 Cells
28.	Efficiency And Safety Of Sequential Treatment Of Icotinib With Chemotherapy In Patients Undergoing Resection Of EGFR Mutation-positive Non-small Cell Lung Cancer
29.	The Relationship With Different Status Of Epidermal Growth Factor Receptor Gene, Clinicopathological Characteristics,prognosis And Therapeutic Effect Of Patients With Non-small Cell Lung Cancer In Qinghai
30.	The Clinical Observation Of Therapeutic Regimens For Slow Progression Advanced NSCLC After First-line EGFR-TKI Therapy
31.	The Efficacy Comparison Of Icotinib And Gefitinib In Stage â…£ Lung Adenocarcinoma Patients With EGFR Sensitive Gene Mutation
32.	Clinical Study Of Modified Xiaoji Decoction Combines With Cytokine Induced Killer Cells And Erlotinib In The Treating Of Advanced Non-small Cell Lung Cancer
33.	Hepatocyte Growth Factor Reduces Sensitivity To The Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Gefitinib,in Lung Adenocarcinoma Cells Harboring Wild-TypeEGFR
34.	Efficiency And Safety Of Intercalated Treatment Of Icotinib With Chemotherapy In Patients Undergoing Resection Of EGFR Mutation-positive Non-small Cell Lung Cancer
35.	Expression And Molecular Mechanism Of Oct4 In The Resistance Of Non-small Cell Lung Cancer To Gefitinib
36.	Circulating Plasma MicroRNAs As Potential Markers To Identify EGFR Mutation Status And To Monitor Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor Treatment In Patients With Advanced Non-small Cell Lung Cancer
37.	The Correlation Between EGFR Mutation Status And EGFR-TKI Efficacy In Non-small Cell Lung Cancer
38.	Treatment And Prognosis Analysis Of 60 Cases Of Different EGFR Mutations Status In Non-small Cell Lung Cancer With Brain Metastasis
39.	Investigation Of EGFR Gene Mutation In Lung Squamous Cell Carcinoma And The Effect Of EGFR-TKI Treatment On Advanced EGFR Mutation
40.	The Clinical Observation Of EGFR-TKI Rechallenge With Antiangiogenic Agents In Advanced NSCLC
<<First <Prev Next> Last>> Jump to